Investigation of the Effectiveness of Short Wave Diathermy Treatment in Patients with Hand Osteoarthritis
Launched by OMER SEZGIN · Dec 12, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how effective a treatment called shortwave diathermy is for people suffering from hand osteoarthritis, which is a type of arthritis that causes pain and stiffness in the hands. The study will compare the effects of this treatment to a placebo (a treatment that does nothing) to see if it can help reduce pain, improve grip strength, and make daily activities easier for participants.
To be eligible for this trial, you need to be between 35 and 75 years old and have a diagnosis of hand osteoarthritis. However, if you have certain health conditions like rheumatoid arthritis, cancer, or uncontrolled systemic diseases, or if you've had recent hand injuries or surgeries, you may not qualify. Participants will receive the treatment in a safe and controlled environment and will be closely monitored throughout the study. This trial is currently recruiting participants, and anyone interested should reach out to learn more.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • To be between 35-75 years old
- • Diagnosis of hand osteoarthritis according to the ACR 1990 Criteria
- Exclusion Criteria:
- • Chronic inflammatory diseases (rheumatoid arthritis, seronegative spondyloarthropathy, gout, hemochramatosis, etc.)
- • Malignancy
- • Having uncontrolled systemic disease (cardiovascular, pulmonary, hematologic, hepatic, renal, endocrinologic)
- • Synovitis, tenosynovitis, entrapment neuropathy, contracture, open wound in hand/wrist
- • History of hand fracture and/or operation
- • Regular use of nonsteroidal anti-inflammatory drugs in the last three weeks
- • Regular use of diaserin, chondroitin sulfate, glucosamine in the last three months
- • Body Mass Index greater than 35
About Omer Sezgin
Omer Sezgin is a dedicated clinical trial sponsor specializing in the development and execution of innovative research studies aimed at advancing medical knowledge and therapeutic interventions. With a strong emphasis on patient safety and regulatory compliance, Omer Sezgin collaborates with leading healthcare professionals and institutions to ensure the integrity and scientific rigor of each trial. Committed to fostering advancements in healthcare, Omer Sezgin leverages cutting-edge methodologies and technologies to facilitate the efficient progression of clinical research, ultimately striving to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
İstanbul, , Turkey
Patients applied
Trial Officials
Nilgün Mesci, Assoc. Prof., MD
Study Chair
Haydarpaşa Numune Training and Research Hospital
Duygu Geler Külcü, Prof., MD
Study Director
Haydarpaşa Numune Training and Research Hospital
Sibel Süzen Özbayrak, MD
Study Director
Haydarpaşa Numune Training and Research Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported